Cohance Lifesciences Ltd has successfully remitted USD 10 million to its subsidiary, NJ Bio Inc., to subscribe for 188,680 Compulsorily Convertible Preferred Shares (CCPS). This capital infusion, approved by the board last year, aims to bolster the US-based firm's growth in the antibody-drug conjugate (ADC) sector. The investment, funded via internal accruals, will see these shares convert to equity after three years, supporting the subsidiary’s ongoing research and manufacturing operations.
Cohance Lifesciences Executes USD 10 Million Investment in NJ Bio Inc.
USD 10 million capital infusion; 188,680 Compulsorily Convertible Preferred Shares subscribed.
Reader Takeaway: Investment strengthens the company's position in specialized ADC therapies, though long-term returns depend on successful operational scale-up.
What just happened
Cohance Lifesciences Ltd has remitted USD 10 million to its US-based subsidiary, NJ Bio Inc. This transaction covers the subscription of 188,680 Compulsorily Convertible Preferred Shares (CCPS) at a price of USD 53 per share. The move follows board approval granted in December 2025 and is being financed entirely through the company’s internal accruals.
Why this matters
NJ Bio Inc. operates as a specialized Contract Research, Development, and Manufacturing Organization (CRDMO) focusing on Antibody Drug Conjugates (ADC) and conjugation-based therapies. By injecting this capital, Cohance is directly funding the subsidiary's growth initiatives and necessary capital expenditures to maintain its technical edge in drug discovery services.
What changes now
The investment locks in capital for the subsidiary’s operations until the CCPS conversion point. The shares are scheduled to convert into equity three years after issuance. The transaction is classified as an arm's length related party transaction.
Context metrics
NJ Bio Inc. reported a turnover of USD 20.6 million in 2023, which grew to USD 32.6 million in 2024, before reporting USD 23.5 million for the 2025 calendar year.
What to track next
Investors should track the operational impact of this capital on NJ Bio's service capabilities and how these investments eventually reflect in the parent company's consolidated margins. The three-year timeline for equity conversion remains the long-term milestone for this stake.